Abiopharma

🔍 Milanova Tsveta (Executive)

Company: AGIOS PHARMACEUTICALS, INC. (AGIO)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Acquired 8,475 shares of Common stock (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 37,665.00 | transaction_form_type: 4
• Sold 2,872 shares of Common stock at $27.02 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 34,793.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 8,475 shares of Restricted stock units (Derivative)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated January 3, 2023.
• F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
• F3: The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.